1 / 25

Nab-paclitaxel Development in Gynecologic Malignancies

Nab-paclitaxel Development in Gynecologic Malignancies. Robert Coleman, MD, FACOG, FACS Director of Clinical Research Department of Gynecologic Oncology MD Anderson Cancer Center. Nab-paclitaxel Gynecologic Malignancy Trials with Enrollment Complete.

uta-price
Download Presentation

Nab-paclitaxel Development in Gynecologic Malignancies

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Nab-paclitaxel Development in Gynecologic Malignancies Robert Coleman, MD, FACOG, FACS Director of Clinical Research Department of Gynecologic Oncology MD Anderson Cancer Center

  2. Nab-paclitaxel Gynecologic Malignancy Trials with Enrollment Complete

  3. Phase II Evaluation of Nab-paclitaxel in Platinum-Sensitive Patients with Recurrent Ovarian, Peritoneal, or Fallopian Tube Cancer • Key Eligibility • Measurable disease by RECIST or elevated CA-125 ( > 70 U/mL) • Prior platinum-based chemotherapy • Platinum treatment-free interval >6 months • n=47 nab-paclitaxel 260 mg/m2 on Day 1 q Q3W x 6 cycles or 8 cycles if patient achieved CR Primary endpoints: Response Rate Secondary endpoints: Progression Free and Overall Survival, Quality of Life, Safety Teneriello, JCO 2009

  4. Patient Characteristics Teneriello JCO 2009

  5. Efficacy Data64% Response Rate with Nab-paclitaxel Monotherapy Teneriello JCO 2009

  6. Safety Data: Adverse Events Teneriello JCO 2009

  7. Phase II Study of nab-paclitaxel Plus Carboplatin in Patients with Recurrent Platinum-Sensitive Ovarian or Primary Peritoneal Cancer • Key Eligibility • Recurrent ovarian or primary peritoneal cancer • Platinum-sensitive • Measurable disease • n = 41 nab-paclitaxel 100 mg/m2 Days 1, 8, 15 q 28 days + Carboplatin AUC 5 or 6 Day 1 q 28 days x 6 cycles Continue nab-paclitaxel until progressive disease or PI-PT discretion Primary endpoints: Antitumor activity and safety Secondary endpoints: Progression-free survival and overall survival Benigno

  8. Patient Characteristics Benigno

  9. Dosing Information • Carboplatin dose AUC 6 administered to first 9 patients • After Grade 4 neutropenia in 3 patients, reduced carboplatin to AUC 5 • 20 patients discontinued treatment for reasons other than toxicity or disease progression Benigno

  10. Safety Data: Adverse Events Benigno

  11. Efficacy Data: SurvivalOver 50% of patients alive at 1-year • Until 9/18/2009, there are 18 patients alive, 21 are dead and one is UNK due to lost of FU, one still active on cycle 44 Benigno

  12. Phase II Evaluation of nab-paclitaxelin Recurrent or Persistent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer • Key Eligibility • Recurrent or persistent ovarian, peritoneal, fallopian tube carcinoma • Platinum-resistant or refractory • Paclitaxel-resistant or refractory • Measurable disease • n = 49 nab-paclitaxel 100 mg/m2 on Days 1, 8, 15 q 28 Treatment until disease progression or unacceptable toxicity Primary endpoints: Antitumor activity and safety Secondary endpoints: Progression Free and Overall Survival R.Coleman

  13. Patient Characteristics • Age: • 50-59 15 (36.6%) • 60-69 14 (34.1%) • 30-49 7 (17 %) • 70-79 5 (12.2%) • Performance Status: • 0 28 (68.3%) • 1 12 (29.3%) • 2 1 ( 2.4%) • Prior Therapy • 1 Reg. 41 (100%) • Immunoth 1 • Hormonal 2 • Race: • White 30 (73.2%) • African American 8 (19.5%) • Hispanic 2 ( 4.9%) • Am Indian 1 ( 2.4%) • Site of Disease • Ovary 35 (85.4%) • Fallopian Tube 1 ( 2.4%) • Peritoneum 5 (12.2%) • Grade • 1 5 (12.2%) • 2 2 ( 4.9%) • 3 34 (82.9%) • Cell Type: • Serous Adeno 29 (72%) R.Coleman

  14. Efficacy Data23% Response Rate with nab-paclitaxel Monotherapy Responses reported in 41 of 49 patients: • 8 patients still to be evaluated R.Coleman

  15. Status of Patients by Cycles Completed55% of patients received more than 3 cycles R.Coleman

  16. Efficacy Data: Overall Survival and Progression-free Survival • Progression-free Survival, median: 4.5 months • Overall survival, median: 18.5 months R.Coleman

  17. Safety Data: Adverse Events • No grade 4 toxicities • Only 1 patient grade 3 neurosensory toxicity AE, adverse event R.Coleman

  18. GOG Phase II Trials in Platinum-Resistant Ovarian Cancer: Active Agents (126 Queue)

  19. Phase II Study of Nab-paclitaxel with Bevacizumab in Patients with Recurrent Platinum-Resistant Primary Epithelial Ovarian or Primary Peritoneal Cancer • Key Eligibility • Recurrent or persistent ovarian, peritoneal cancer • Platinum-resistant within 6 months • Measurable disease • n = 48 Nab-paclitaxel 100 mg/m2 on Days 1, 8, 15 + Bevacizumab 10mg/kg Days 1, 15 Q28d Treatment until disease progression or unacceptable toxicity Primary endpoints: Duration of objective response, safety Secondary endpoints: Duration of progression-free survival, overall survival, quality of life Tillmans

  20. Efficacy Data48% response rate with Nab-paclitaxel + Bevacizumab • Response rate: 48% • Stable Disease: 25% Tillmanns

  21. Efficacy: Progression-free Survival • Median Progression-free Survival: 8.26 months Tillmanns

  22. Safety Data: Grade 3 / 4 Adverse Events* * One Death, NOS Tillmanns

  23. Phase II Single Agent Bevacizumab Efficacy and Safety *Trial terminated prematurely due to incidence of GI perforation. Burger RA, et al. J Clin Oncol. 2007;25(33):5165-5167; Cannistra SA, et al. J Clin Oncol. 2007;25(33):5180-5186.

  24. Nab-paclitaxel Gynecologic Malignancy Trials Ongoing

  25. Ovarian Cancer Treatment ParadigmWhere does nab-paclitaxel fit into this treatment paradigm? #2 #3 1st relapsed Platinum-based regimen Non-platinum-based regimens Platinum-sensitive • Carbo + Taxol ± Avastin • Carbo + Gemzar ± Avastin • Carbo + Doxil • Doxil + Trabectedin • Doxil • Hycamtin #1 Surgery Front-line Platinum-based regimen • Carbo + Taxol ± Avastin #3 Non-platinum-based regimen Platinum-resistant • Doxil • Hycamtin Platinum-sensitive = >6 months before recurrence after front-line platinum-based chemo Platinum-resistant = <6 months before recurrence after platinum-based chemo

More Related